Selection of pfmdr1 mutations after amodiaquine monotherapy and amodiaquine plus artemisinin combination therapy in East Africa
Selection of pfmdr1 mutations after amodiaquine monotherapy and amodiaquine plus artemisinin combination therapy in East Africa
复制标题
DOI：
10.1016/j.meegid.2007.03.005
复制
发表时间：
2007-09-01
影响因子：
3.2
通讯作者：
Bjorkman, Anders
中科院分区：
文献类型：
--
作者：
Holmgren, Gabrielle;Hamrin, Johan;Bjorkman, Anders
尽管基于青蒿素的联合疗法（ACT）具有药效学优势，并且对阿莫地喹（AQ）/去乙基阿莫地喹（DEAQ）和青蒿琥酯（ART）的耐受性具有一些潜在相反的分子机制，如果这两种药物不能确保相互预防药物的选择和传播，则存在功效迅速衰减的风险-我们研究了在AQ单药治疗后复发感染中选择的pfcrt和pfmdrI基因突变是否也在AQ加ART联合治疗后选择。
Despite the pharmacodynamic advantages with artemisinin-based combination therapy (ACT) and some potentially opposite molecular mechanisms of tolerance to amodiaquine (AQ)/desethylamodiaquine (DEAQ) and artesunate (ART), there is a risk for rapid decay in efficacy if the two drugs are unable to ensure mutual prevention against a selection and spread of drug-resistant parasites.We have studied if mutations in the pfcrt and pfmdrI genes selected in recurrent infections after AQ monotherapy are also selected after AQ plus ART combination therapy.Samples for molecular analysis were derived from three clinical trials on children